Soligenix, Inc. · NASDAQ:SNGX
Soligenix — Investor Presentation (May 2021)
24 slides from Soligenix's investor presentation, May 2021
Slide 1: Rising to the Challenges of Rare Disease Treatment
Rising to the Challenges of Rare Disease Treatment NASDAQ: SNGX
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products
Slide 3: Company Description
3 Company Description Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need Two areas of focus: A Specialized BioTherapeutics segment dedicated to the development of products for orph
Slide 4: Investment Highlights
4 Investment Highlights Multiple products with fast track and/or orphan designation, with potential for significant commercial returns Phase 3 assets, one with successful data readout o Cutaneous T-cell lymphoma (HyBryte™) – Positive statistically significant final results achieved; study comple
Slide 5: Development Pipeline – Rare Diseases
5 Development Pipeline – Rare Diseases Product Candidates Preclinical Phase 1 Phase 2 Phase 3 Market Specialized HyBryte™ (SGX301) BioTherapeutics Cutaneous T-Cell Lymphoma (CTCL) ORPHAN & FAST TRACK DESIGNATION Positive primary + Cycle 2 & 3 results SGX942 Oral Mucositis in Head & Neck FAST TRACK D
Slide 6: Multiple Potential Value Drivers
6 Multiple Potential Value Drivers 2020 2021** 2022** Ph. 3 final Cycle 3 + AAD/SID Ph. 3 data 2H: EU regulatory – 1H: (US) NDA 2H: (EU) MAA HyBryte™* follow-up data CTCL presentations (e.g., PIP/ILAP) submission CTCL submission CTCL Preclinical 2H: Preclinical 2H: Initiate Phase 2 RiVax®* animal da
Slide 7: Total Addressable Global Market
7 Total Addressable Global Market $350 Assumptions(1) $300 $300 Cutaneous T-Cell Lymphoma $250 27,000 Patients US $250 20,000 Patients EU Pediatric Crohn’s Disease $200 $200 80,000 Patients US $ Millions $200 80,000 Patients EU Acute Radiation Enteritis in $150 Colorectal Cancer 50,000 Patients US $
Slide 8: Specialized BioTherapeutics
8 Specialized BioTherapeutics Targeted Approach to Treating Oncology & Inflammation
Slide 9: Specialized BioTherapeutics Segment
9 Specialized BioTherapeutics Segment Commercial Targets – Unmet Medical Needs in Oncology and Inflammation Product Candidates Preclinical Phase 1 Phase 2 Phase 3 Market Specialized BioTherapeutics HyBryte™ (SGX301) ORPHAN & FAST TRACK DESIGNATION Positive primary Cutaneous T-Cell Lymphoma (CTCL) +
Slide 10: Cutaneous T-Cell Lymphoma – Disease Overview
10 Cutaneous T-Cell Lymphoma – Disease Overview Cutaneous T-cell lymphoma (CTCL) o Rare class of Non-Hodgkin's Lymphoma (NHL) o Malignant T-cells migrate to the skin o Cancer forms patches, lesions or tumors CTCL affects over 40,000 NHL patients worldwide; currently no cure o $250 million total
Slide 11: HyBryte™ (SGX301) – Synthetic Hypericin Ointment + Light Activation, First-in-Class
HyBryte™ (SGX301) – Synthetic Hypericin 11 Ointment + Light Activation, First-in-Class Treatment safe and well-tolerated o Minimal reported adverse events ‒ Other CTCL treatments characterized by acute and chronic side effects o Uses visible fluorescent light ‒ Not carcinogenic unlike other UV pho
Slide 12: HyBryte™ – Pivotal Phase 3 Clinical Trial
12 HyBryte™ – Pivotal Phase 3 Clinical Trial Highly powered, double-blind, placebo-controlled, randomized o Randomized 2:1 (HyBryte™ [synthetic hypericin 0.25%] : placebo) HyBryte™ Placebo o Cycle 1 complete: Primary Endpoint (response rate) Cycle 1: statistically significant (p=0.04) 118 subjects
Slide 13: Phototherapy a mainstay treatment of early stage CTCL
Phototherapy a mainstay treatment of 13 early stage CTCL HyBryte™ Treatment Regimen Treating dermatologists are experienced administering phototherapy Approximately 80% of community dermatology practices have light units available 100% of the ~50 US CTCL clinics currently administer UV phototh
Slide 14: Dermatologist KOLs play pivotal role in treatment of early stage CTCL
Dermatologist KOLs play pivotal role in 14 treatment of early stage CTCL Most CTCL patients who go to a Key Opinion Leader (KOL) for diagnosis will remain with that KOL for their care and treatment For those that return to their referring physician (typically for logistical reasons or travel dis
Slide 15: Significant opportunity for improvement to current treatment paradigm in early stage CTCL
15 Significant opportunity for improvement to current treatment paradigm in early stage CTCL Early Stage CTCL Treatment Paradigm Current Treatment Landscape Because of chronic nature of early stage CTCL and long-term treatment cycles, clinicians choose Empiric Tx therapies with better safety Topic
Slide 16: Advantages to commercializing CTCL in the US
16 Advantages to commercializing CTCL in the US: smaller sales force and market access support A concentrated prescriber base Payers are likely to cover the drug allows for an efficient sales force and light treatment if shown to be footprint safe and efficacious o Planned launch focused on high
Slide 17: HyBryte a Significant Near Term Commercial Opportunity Addressing a Clear Unmet Need
17 HyBryte™ a Significant Near Term Commercial Opportunity Addressing a Clear Unmet Need Clinicians see need for additional treatment options with fewer side effects Most patients cycle through several treatments over course of their disease Unmet Need Chronic nature of early stage CTCL and di
Slide 18: Public Health Solutions
18 Public Health Solutions Addressing Critical Concerns for Industry and Government
Slide 19: Public Health Solutions Segment
19 Public Health Solutions Segment Funded by Government – Medical Countermeasures (MCMs) for Civilian and Military Use Public Health Product Candidates (FDA Animal Rule) Proof-of-Concept IND Phase 1 Phase 2/3 Market Solutions** RiVax® + ThermoVax® – Vaccine NIH Contract Awards of $30M to date; ORPHA
Slide 20: RiVax® – Ricin Toxin Vaccine Candidate
20 RiVax® – Ricin Toxin Vaccine Candidate Ricin toxin vaccine of rising Heat-stable ricin vaccine provided interest to US and other countries 100% protection in a non-human primate due to recent terrorist threats and aerosol challenge model ease of castor bean procurement and ricin production Demo
Slide 21: CiVax™ – COVID-19 Vaccine Candidate
21 CiVax™ – COVID-19 Vaccine Candidate Spike protein and CoVaccine HT™ Pandemic response will require adjuvant demonstrated (here and here): many different vaccines to produce adequate global coverage Balanced antibody response (including Th1) Market Rapid distribution enabled by Strong neut
Slide 22: Experienced Management and Board of Directors
22 Experienced Management and Board of Directors • 30 years of experience • 25 years of experience Gregg Lapointe, Christopher J. • Discovery Laboratories (COO) • Cerium Pharmaceuticals (CEO) CPA, MBA Schaber, PhD • Acute Therapeutics (Co-Founder) • Formerly of Sigma-Tau Pharmaceuticals, Chairman, •
Slide 23: In Summary
23 In Summary Multiple products with fast track and/or orphan designation, with potential for significant commercial returns Phase 3 assets, one with successful data readout o Cutaneous T-cell lymphoma (HyBryte™) – Positive statistically significant final results achieved; study complete – New d
Slide 24: Thank you
24 Thank you www.soligenix.com NASDAQ: SNGX